Primary Objective:
1. To assess resectability rate in patients undergoing gemcitabine plus Avastin-based
chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreas.
Secondary Objectives:
1. To assess disease free survival and overall survival
2. To assess margin resection rate (R0 vs. R1) in these patients
3. To assess patterns of failure